Cefamid

Quick links to important sections

Cefamid

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefamid

Property Description
Active Ingredient Cephradine (Cefradine)
Form Capsule, Tablet, Oral Suspension, Powder for Injection
Pharmacological Class First-generation Cephalosporin Antibiotic
Common Use Systemic Anti-infective Agent
Origin Semi-Synthetic Compound

What Type of Medicine is Cefamid and Its Active Ingredient?

Cefamid is a systemic, prescription-only anti-infective agent whose single active ingredient is the chemical substance Cephradine. Pharmacologically, it is classified as a First-generation Cephalosporin antibiotic, placing it within the larger family of Beta-lactam antimicrobial drugs. The versatility of Cephradine is clinically recognized for its reliable efficacy against common Gram-positive bacteria, a focus typically associated with this first-generation classification. Cephradine is a semi-synthetic compound, derived from natural precursors but manufactured through controlled chemical synthesis.

Composition and Available Pharmaceutical Preparations

The medicine is supplied for systemic administration through both the oral and parenteral routes, a key feature that provides flexibility in patient care. For the oral route, Cefamid is available as capsules and tablets, as well as a liquid oral suspension, often used for pediatric patients. For situations requiring non-oral use, it is presented as a powder for injection to be reconstituted with sterile diluents for either intravenous or intramuscular routes. The ability to transition patients from injection to an oral form of the same medicine is supported by medical practice for sequential therapy.

General Purpose: How Does This Antibiotic Function?

The primary general purpose of Cefamid is the effective eradication of susceptible bacterial infections throughout the body, such as common skin or soft tissue infections. Its core action is bactericidal, meaning it actively kills the targeted pathogens rather than merely inhibiting their growth, a function consistent with the Beta-lactam class. The mechanism involves interfering with the structural integrity of the bacterial cell. Specifically, Cephradine disrupts the final cross-linking step of bacterial cell wall synthesis, leading directly to the death and elimination of the targeted organisms. This mechanism makes Cefamid a tool for resolving underlying bacterial diseases.

Regulatory References

  1. NIH LactMed Database

What side effects are possible with Cefamid?

Possible Side Effects and Safety Information

The safety profile of Cefamid (Cephradine), a first-generation cephalosporin, is structured around adverse reactions that typically involve the gastrointestinal system and hypersensitivity responses, based on official regulatory documents.

General Adverse Reaction Profile

The most commonly documented adverse reactions include nausea, vomiting, diarrhea, and abdominal pain. Skin reactions such as rash, urticaria (hives), and pruritus (itching) are also frequently listed. Less common effects involve the nervous system (e.g., dizziness, headache) and candidiasis (superinfection), often in the oral or genital areas.


Serious Adverse Reactions and Safety Constraints

Official labeling identifies several severe, though rare, adverse reactions. These include anaphylaxis (a life-threatening allergic reaction) and pseudomembranous colitis (a serious form of antibiotic-associated diarrhea). The potential for seizures is a documented neurotoxic risk, particularly noted in governmental safety reviews concerning unadjusted use in patients with compromised kidney function. Rare blood disorders, such as hemolytic anemia and leukopenia, are also recognized.


Population-Specific Safety Notes

The official prescribing information includes specific safety constraints for certain patient groups. A dosage adjustment is mandatory for individuals with renal impairment to prevent drug accumulation and mitigate the risk of neurotoxicity. Furthermore, Cephradine may interfere with certain laboratory analyses, causing false-positive results in specific urine glucose tests and the Coombs' test. The drug is contraindicated in patients with a history of documented hypersensitivity to cephalosporins.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the manifestations of Cefamid (Cephradine) overdose primarily through gastrointestinal and neurological effects. Overdose is typically associated with non-specific gastrointestinal disturbances, including nausea, vomiting, and diarrhea.

The most serious documented outcome is the potential for seizure (convulsions), which necessitates urgent action.


Required Emergency Actions

Action Area Official Regulatory Statement
Immediate Help-Seeking Seek emergency medical attention immediately if overdose is suspected due to the risk of severe outcomes.
Official Treatment Strategy Treatment is largely symptomatic and supportive. Gastric lavage may be considered necessary following the ingestion of a large amount of the medicine.
Antidote / Elimination No specific antidote is known. The drug may be removed from the body using hemodialysis or peritoneal dialysis to accelerate elimination.

Official regulatory documents define the overdose profile by listing the expected gastrointestinal disturbances and highlighting the critical potential for seizure as a severe systemic risk. This high-risk presentation immediately mandates the explicit regulatory instruction to seek emergency medical attention for all suspected cases. Management procedures focus on supportive care and the removal of the unabsorbed drug.

Therapeutic Uses of Cefamid

Cefamid (Cephradine) is generally applied in clinical settings that involve acute or unstable bacterial infection patterns. Its core therapeutic benefit is linked to addressing the bacterial cause, which contributes to easing the overall symptom load experienced by the patient.

The medicine is considered relevant in several common therapeutic domains. Its use is relevant in conditions such as respiratory tract infections (e.g., pharyngitis, acute bronchitis, and tonsillitis), urinary tract infections (UTIs), and skin and soft tissue infections (e.g., cellulitis). The medication is applied in addressing symptom clusters related to inflammatory states, which include localized pain, swelling, and systemic fever.

“Applied in scenarios where additional management of discomfort is required, Cefamid assists with maintaining functional stability.”

In clinical scenarios, the medication is also commonly used for surgical prophylaxis, meaning it is administered prior to certain procedures to help prevent potential post-operative infection. This use provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Focus on Acute Discomfort

Quick Fact: Focus on Acute Discomfort Cefamid is used for managing symptoms that create noticeable physiological strain, particularly those associated with inflammatory or irritative processes in the respiratory, urinary, and dermal systems.

Regulatory References

  1. NIH NCBI Bookshelf overview on First-Generation Cephalosporins

Eligibility and Restrictions for Use

Cefamid (Cephradine) eligibility rules are strictly defined by regulatory authorities and based on patient history, age, and coexisting conditions. The primary rules for use are structured as follows:

Contraindications (Who Must Not Use)

  • Hypersensitivity: The medicine is absolutely contraindicated for individuals with a known allergy to the cephalosporin group of antibiotics or any component of the Cefamid formulation. Extreme caution is also required for patients with a documented history of severe penicillin allergy due to potential cross-allergenicity.
  • Route Restriction: The drug must not be administered via the intrathecal route (into the spinal canal).

Conditional Use and Special Populations

Population Group Eligibility Status Regulatory Basis
Impaired Renal Function Use is allowed, but strictly conditional. Requires monitoring and a modified dosage regimen to prevent drug accumulation.
Infants (< 9 Months) Use is not established or documented for safety and efficacy in this age group.
Pregnancy Use is classified by some authorities as Category B, but it is not generally recommended (especially in the first trimester) unless clearly needed.
Breastfeeding Mothers Use requires caution because the active ingredient is excreted in breast milk.
History of Colitis Use requires caution due to the associated risk of developing antibiotic-related diarrhea.

What should I know about interactions with other medicines?

Cefamid Interactions with other medicines and products

Official regulatory documentation identifies specific patterns of interaction for Cefamid (Cephradine) based on its renal elimination and class-specific pharmacodynamic properties. No combinations are formally labeled as contraindicated in the reviewed authoritative sources.

Category Official Regulatory Documentation Statement
Interacting Medicinal Products Probenecid; Loop Diuretics; other nephrotoxic agents (e.g., Aminoglycosides, Vancomycin); bacteriostatic antibiotics; products containing zinc.
Mechanistic Basis Inhibition of renal tubular secretion (by Probenecid); additive organ toxicity; interference with absorption (by zinc compounds).
Timing-Based Rules Products containing zinc must be administered at least three hours after Cefamid to prevent reduced oral absorption.
Diagnostic Interference The drug can cause false-positive results when testing for urine glucose using diagnostic products based on cupric sulfate reduction (e.g., Clinitest).

Official Interaction Statements:

  • Probenecid co-administration is documented to raise Cefamid serum concentrations and delay excretion by inhibiting renal tubular secretion.
  • Co-administration with Loop Diuretics and other nephrotoxic medicinal products is associated with an increased risk of nephrotoxicity.
  • The combination of Cefamid with certain bacteriostatic antibiotics may result in documented interference with its bactericidal activity.

The overall interaction structure is defined by three categories of constraints: a pharmacokinetic risk of increased drug exposure when combined with probenecid; a pharmacodynamic caution regarding additive organ toxicity; and a required timing separation for oral administration with zinc products due to absorption interference. Regulatory documents formally classify these interactions as requiring careful consideration or mandatory timing separation.

Mechanism of Action

Covalent Inhibition of Bacterial Cell Wall Synthesis

Cefamid (Cephradine) acts by targeting bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are critical for constructing the rigid peptidoglycan cell wall. The drug's beta-lactam structure binds covalently and irreversibly to these proteins, inhibiting the final cross-linking step of the cell wall assembly.


Induction of Fatal Osmotic Lysis

The direct consequence of blocking the cell wall assembly pathway is the destruction of the bacterial cell's structural integrity. The compromised, fragile cell wall cannot withstand the high internal fluid pressure of the bacterium, leading to immediate osmotic lysis (rupture and death of the cell). This molecular mechanism results in bactericidal activity (bacterial cell lysis and death).


Mechanistic Constraints and Evasion Pathways

This mechanism is constrained by a bacterial ability to produce beta-lactamase enzymes, which hydrolyze and inactivate the drug before it reaches the PBP target. Furthermore, the mechanism fails against bacterial strains that have evolved or acquired altered Penicillin-Binding Proteins with a low binding affinity for the drug.

Dosage and Administration Information

How Cefamid is Used: Official Dosing and Administration

Cefamid (Cephradine) is a prescription antibiotic administered based on strict guidelines outlined in official prescribing information.

Approved Administration and Dosage Forms

Cefamid is intended for systemic administration via both oral and parenteral routes. Official forms include Capsules and Tablets, an Oral Suspension for liquid use, and Powder for Injection for parenteral administration (Intravenous or Intramuscular).

Standard Dosing and Frequency

Regimen Component Oral Dosing (Typical Range) Parenteral Dosing (IV/IM)
Typical Dose per Administration 250 mg to 500 mg 500 mg to 1 g
Total Daily Dose (Maximum) Typically up to 4 grams (4,000 mg) Up to 8 grams (8,000 mg) for severe cases
Dosing Frequency Every 6 hours (QID) or Every 12 hours (BID) Every 6 hours (QID)

The total daily dose is divided and administered at regular intervals, often every 6 or 12 hours. Oral forms may be taken with or without food.

Procedural Instructions and Course Duration

Treatment duration typically ranges from 7 to 14 days. Official guidance mandates continuing treatment for a minimum of 48 to 72 hours after clinical symptoms have resolved. The Powder for Injection requires reconstitution with sterile diluents prior to use; IV administration must be performed slowly (e.g., over 3 to 5 minutes).

Population-Specific Use

  • Pediatric Patients: Dosing is calculated based on body weight (mg/kg/day) and divided into multiple doses.
  • Renal Impairment: The dosage or the administration interval must be adjusted (reduced/extended) according to the patient’s kidney function (creatinine clearance) to prevent accumulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefamid

This section provides a patient-friendly overview of the official research evidence that has been the subject of research exploring how Cefamid (Cephradine) was evaluated in clinical settings, focusing on the study structure, the outcomes researchers monitored, and areas where evidence is limited or ongoing. This information is descriptive and does not constitute medical advice or treatment recommendations.


Evidence for Use in Acute and Recurrent Infections

Clinical research, including randomized trials and comparative studies, has studied Cefamid in contexts involving bacterial infections of the skin, soft tissues, urinary tract, and respiratory tract. The evidence generally centers on research exploring changes in symptoms and the study of pathogen clearance rates over defined time intervals.

  • Urinary Tract Infections (UTIs): Studies have evaluated Cefamid's use in patients experiencing acute, uncomplicated UTIs. Research examined bacteriological clearance (the process of studying how the infecting organism was removed from the urine) and clinical response (monitoring outcomes related to physical discomfort). For complex presentations, data for certain groups remain insufficient, and follow-up durations were limited in many acute studies.

  • Skin and Soft Tissue Infections: Clinical trials have explored Cefamid's application in patients with bacterial infections, monitoring microbiological eradication (the process of studying how the pathogen was removed) and the clinical response. Comparative research documented clinical outcome measurements in the studied populations over a defined period.

  • Respiratory Tract Infections: Cefamid was studied for use in acute respiratory infections, such as pharyngitis. Studies report how symptoms evolved in the observed populations, and findings generally align with the overall understanding that antibiotics are used for infections caused by susceptible bacteria.

Evidence in Surgical Prophylaxis Settings

Research examined Cefamid, as a first-generation cephalosporin, administered pre-operatively, with research exploring the incidence of surgical site infections (SSI). Systematic reviews generally reported outcomes where the incidence of SSIs was assessed when comparing antibiotic use to no prophylaxis. While another agent from this class (Cefazolin) is widely referenced in this context, Cefamid belongs to the same class.

What is Still Uncertain About Cefamid

Key limitations acknowledged in the scientific literature include: the evidence quality varies across studies, as much of the core clinical research is older and may not meet contemporary methodological standards. Sample sizes were modest in some studies, and comparative evidence is lacking for Cefamid against all current treatment standards.

Key Studies & References Overview on First-Generation Cephalosporins - NIH NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Cefamid (FAQ)

Q: How long does it usually take for Cefamid to start working?

A: Studies and official information indicate that the onset of action for Cefamid (Cephradine) in its oral form typically occurs within one hour of being taken. However, the time it takes for a patient to feel a noticeable improvement in symptoms (the clinical response) can vary.

Q: Can Cefamid affect birth control pills?

A: The official product labeling for Cephradine does not list an interaction with oral contraceptive pills. The official documentation does not list reduced efficacy of birth control as a reported interaction with this antibiotic.

Q: Is it okay to drink alcohol while taking Cefamid?

A: Official drug information cautions against alcohol consumption during treatment with Cefamid. This is because alcohol consumption may increase the risk or severity of certain side effects, such as blurred vision or dizziness.

Q: What should I do if I miss a dose of Cefamid?

A: General regulatory advice describes taking the missed dose as soon as it is remembered. However, if the time is close to the next scheduled dose, regulatory advice generally cautions against taking two doses together to compensate for a missed dose.

Q: Do older adults use Cefamid differently?

A: The official prescribing information states that dosage adjustments may be necessary for older adult patients. This is primarily due to the common age-related decrease in kidney function, as the medicine is cleared through the kidneys.

Q: What happens if I stop taking Cefamid early?

A: The regulatory label explicitly mandates that treatment should continue for a minimum duration. Completing the full prescribed course is emphasized in official guidance to support the complete eradication of bacteria and help prevent antibiotic resistance.

Q: How long does Cefamid stay in your system?

A: Official pharmacokinetics data indicate that the elimination half-life of Cephradine in individuals with normal kidney function is approximately half an hour to two hours. The drug is then primarily excreted via the urine.

Q: Does Cefamid cause sensitivity to the sun?

A: No; Cefamid (Cephradine) is not listed in the official labeling documents as a photosensitizing drug. This specific risk is documented for certain other antibiotic classes, but not for this one.

Q: What should I know about Cefamid and liver issues?

A: Official safety advice mentions that individuals with a history of liver disease are typically subject to specific consideration or monitoring by a healthcare provider, as they may need to adjust the dose or prescribe an alternative medicine.

Q: Is there a risk of tendon damage with Cefamid?

A: No; the official labeling for Cephradine, a cephalosporin antibiotic, does not list tendon damage (tendinitis or tendon rupture) as a possible adverse reaction. This specific safety concern is typically associated with a different class of antibiotics.

Q: Is it safe to take Cefamid with pain relievers like ibuprofen?

A: The official label does not list a specific interaction with common non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen. However, official guidance indicates that patients with reduced kidney function who are taking NSAIDs alongside antibiotics may require increased monitoring.

Q: Does Cefamid interact with medications for diabetes?

A: The label notes that the drug can cause a false-positive result when patients test for urine glucose using specific diagnostic products (cupric sulfate reduction tests). No direct interaction with oral diabetes medications is generally noted in regulatory documents.

Q: Does Cefamid cause drowsiness or fatigue?

A: Official labeling documents for Cephradine list central nervous system effects such as dizziness and headache as potential side effects. Some regulatory sources also note potential restlessness or drowsiness, which may affect the ability to drive or operate machinery.

Q: What is the difference between Cefamid and penicillin?

A: Cefamid (Cephradine) is formally classified as a First-generation Cephalosporin antibiotic, while penicillin belongs to the Penicillin class. Though both are types of Beta-lactam antibiotics, their specific chemical structures differ, leading to different allergy and activity profiles.

Q: Is Cefamid a strong or mild medication?

A: Cefamid is classified as a First-generation Cephalosporin, which defines its spectrum of activity. This class is characterized by activity against common Gram-positive bacteria, and is known to possess bactericidal action (meaning it works to kill bacteria) against susceptible organisms.

Q: Why do people sometimes get a rash from Cefamid?

A: The rash is officially documented as a common manifestation of a hypersensitivity reaction (allergy) to the drug. This type of immune response is typical for the cephalosporin and penicillin classes due to shared structural elements.

Q: How does Cefamid compare to similar medications (in its class)?

A: Cefamid (Cephradine) is in the First-generation Cephalosporin class, alongside agents such as Cefazolin and Cephalexin. These agents share similar pharmacological properties, focusing primarily on Gram-positive coverage and being used for similar documented indications.

Q: Can Cefamid be crushed or chewed?

A: Official product information states that the oral capsule and tablet forms are not intended to be crushed, chewed, or broken. This is generally due to the need to maintain the drug’s formulation and intended release properties.

Q: Does Cefamid have any known interactions with supplements?

A: The official label specifically warns of an interaction with products containing zinc, which are common in multivitamins and supplements. These compounds can reduce the absorption of Cephradine, and official guidance documents recommend a separation in the timing of administration for these products.

Q: Is Cefamid considered a broad-spectrum antibiotic?

A: Cefamid, as a First-generation Cephalosporin, is primarily active against Gram-positive bacteria, with limited Gram-negative coverage. This profile is generally considered to place it on the narrower end of the spectrum when compared to newer, later-generation cephalosporins.

Q: Why is it important to know who cannot use Cefamid?

A: Knowing the contraindications is important to prevent serious adverse outcomes, such as a life-threatening allergic reaction (anaphylaxis) in hypersensitive individuals. It also helps prevent toxic drug accumulation in patients whose bodies cannot properly clear the medicine.

Q: Is it possible to be allergic to Cefamid without knowing?

A: Yes, while the label prohibits use in those with a known allergy, an allergic reaction can occur upon first exposure to any medication. Hypersensitivity to Cephradine or related antibiotics can develop even if an individual has never taken it before.

Q: Is Cefamid a branded or generic drug name?

A: Cephradine is the generic name for the active chemical ingredient. Cefamid is one of the many brand names under which the generic drug Cephradine has been marketed worldwide by various manufacturers.

Q: Does Cefamid interact with antacids or iron supplements?

A: Although the Cephradine label primarily names zinc, related cephalosporins carry warnings that iron supplements and antacids can interfere with absorption. Patients are generally advised to consider separating the administration of Cefamid from these products to ensure proper drug uptake.

Q: Does taking Cefamid affect the gut microbiome?

A: The official label lists adverse effects that result from disruption of the gut's normal microbial balance, such as antibiotic-associated diarrhea. In rare cases, this disruption can lead to a serious condition known as pseudomembranous colitis.

Q: What happens if I forget to refrigerate the liquid Cefamid?

A: The reconstituted liquid suspension must be stored in the refrigerator to maintain its chemical stability and full effectiveness for the designated discard period. If the recommended refrigeration conditions are not maintained, its potency may be reduced before the discard date is reached.

How should Cefamid be stored and disposed of?

How to Store and Dispose of Cefamid?

The storage and disposal of Cefamid (Cephradine) are governed by specific regulatory requirements to maintain the medicine's integrity and protect the environment.

Storage and Stability

Form Temperature Requirement Stability Constraint
Solid Forms (Capsules, Tablets) Store at temperatures not exceeding 30 C (Room Temperature). Must be kept in the original container, tightly closed, and protected from light and moisture.
Reconstituted Suspension Store under refrigeration, between 2 C and 8 C, for extended stability. Do not freeze. The suspension must be discarded after the defined in-use period (e.g., 7 or 14 days), even if refrigerated.

Mandatory Disposal and Safety Rules

All unused or expired Cefamid must be stored out of the sight and reach of children to prevent accidental ingestion. Disposal must follow official pharmaceutical take-back programs or local regulations. To prevent environmental contamination, it is mandatory to not dispose of this antibiotic by flushing it down a toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefamid found in:

A-Z Index: